XM does not provide services to residents of the United States of America.

Health insurer Centene beats profit targets on commercial plan strength



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Health insurer Centene beats profit targets on commercial plan strength</title></head><body>

Adds background on rivals in paragraphs 3 and 4, details on membership in paragraph 8

Oct 25 (Reuters) -Centene CNC.N beat Wall Street estimates for third-quarter profit on Friday, as strength in its commercial insurance business outweighed the impact of high costs related to its government-backed Medicaid plans for low-income people.

Shares of the health insurer jumped 11.65% to $68.80 in premarket trading after the company also maintained its annual profit forecast of greater than $6.80 per share, above analysts' expectation of $6.73, according to data compiled by LSEG.

Wall Street expectations have been subdued after peers UnitedHealth and Elevance ELV.N, which also offer Medicaid plans, warned of a hit from high demand for healthcare services, bringing down the sentiment for the health insurance industry.

UnitedHealth also expects pressure across its government-supported health insurance businesses in 2025.

Centene reported a medical loss ratio — the percentage of premiums spent on medical care — of 89.2% for the quarter ended Sept. 30, compared with analysts' estimate of 88.03%, according to data compiled by LSEG.

The higher costs also stemmed from a reassessment that has led to an increase in the number of sick patients in insurers' Medicaid membership profile.

States have been re-determining Medicaid eligibility after a federal policy that required insurers to keep low-income Americans enrolled in health plans during the COVID-19 pandemic ended last year.

For the third quarter, Centene's total Medicaid memberships fell 14% to 13.07 million members from a year earlier, whereas commercial plan memberships grew 20% to 4.93 million.

On an adjusted basis, the health insurer earned $1.62 per share, compared with analysts' average estimate of $1.33 per share.




Reporting by Amina Niasse in New York City, Sriparna Roy and Unnamalai L in Bengaluru; Editing by Shilpi Majumdar and Shinjini Ganguli

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.